LÁZNIČKOVÁ, Petra, Tomáš KEPÁK, Marcela HORTOVÁ KOHOUTKOVÁ, Luděk HORVÁTH, Kateřina SHEARDOVÁ, Rafał MARCINIAK, Carmine VACCA, Michaela SIKLOVA, Teresa ZELANTE, Lenka ROSSMEISLOVA, Zdenka KŘENOVÁ, Jaroslav ŠTĚRBA, Kamila BENDICKOVA and Jan FRIČ. Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence. EUROPEAN JOURNAL OF IMMUNOLOGY. HOBOKEN: WILEY, 2020, vol. 50, No 12, p. 2092-2094. ISSN 0014-2980. Available from: https://dx.doi.org/10.1002/eji.202048541.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Childhood survivors of high-risk neuroblastoma show signs of immune recovery and not immunosenescence
Authors LÁZNIČKOVÁ, Petra (203 Czech Republic, belonging to the institution), Tomáš KEPÁK (203 Czech Republic), Marcela HORTOVÁ KOHOUTKOVÁ (203 Czech Republic), Luděk HORVÁTH (203 Czech Republic), Kateřina SHEARDOVÁ (203 Czech Republic), Rafał MARCINIAK (203 Czech Republic), Carmine VACCA (380 Italy), Michaela SIKLOVA (203 Czech Republic), Teresa ZELANTE (380 Italy), Lenka ROSSMEISLOVA (203 Czech Republic), Zdenka KŘENOVÁ (203 Czech Republic), Jaroslav ŠTĚRBA (203 Czech Republic), Kamila BENDICKOVA (203 Czech Republic) and Jan FRIČ (203 Czech Republic, guarantor).
Edition EUROPEAN JOURNAL OF IMMUNOLOGY, HOBOKEN, WILEY, 2020, 0014-2980.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.532
RIV identification code RIV/00216224:14110/20:00116320
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/eji.202048541
UT WoS 000560133400001
Keywords in English adverse late effects; childhood; immune recovery; immunosenescence; neuroblastoma
Tags 14110513, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 4/3/2021 10:34.
Abstract
Neuroblastoma survivors show signs of immunosenescence early after therapy in CD8(+)T cell compartment and elevated plasma TNF-alpha but in later follow-up immune recovery comes into play. Whether the recovery phenotype is long lasting or transient remains to be elucidated, however, late adverse effects often occur in childhood cancer survivors.
Links
MUNI/A/1409/2019, interní kód MUName: Personalizovaná léčba v dětské onkologii: na cestě k "liquid dynamic medicine" a "N-of-1 clinical trials"
Investor: Masaryk University, Category A
PrintDisplayed: 28/7/2024 05:23